9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Get Help 24/7
logo
Get Help 24/7
mobile logo
Search
 

Archive

25 April
0 Comments
Sticky

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

Posted by Goldberg, Persky & White P.C.

Condition Lung Cancer|Malignant Mesothelioma|Metastatic Cancer|Thymoma and Thymic Carcinoma Estimated Enrollment: 30 Age Group: Child, Adult, Senior Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CDR0000068889|P30CA016042|UCLA-9908024|NCI-G01-2011 Study First Received: September 13, 2001 Last Updated: October 28, 2015 Estimated Primary Completion Date: December 2006 Primary Outcome Measures: Sponsors and Collaborators: Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00024076...

Continue reading
25 April
0 Comments
Sticky

Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)

Posted by Goldberg, Persky & White P.C.

Condition Metastatic Non-squamous Non Small Cell Lung Cancer Estimated Enrollment: 201 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CBP08-02 Study First Received: July 17, 2009 Last Updated: July 29, 2013 Estimated Primary Completion Date: July 2013 Primary Outcome Measures: The primary efficacy endpoint is Progression free survival, analyzed in the treated population. PFS is assessed from randomization until either tumor progression, as per RECIST criteria, or until death due to any reason.|Objective response rate (CR + PR): response is to be assessed according to RECIST criteria (see Section 7.1), with...

Continue reading
25 April
0 Comments
Sticky

Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy

Posted by Goldberg, Persky & White P.C.

Condition Abdominal Neoplasm|Colonic Neoplasm|Mesothelioma|Peritoneal Neoplasm Estimated Enrollment: 188 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 000069|00-C-0069 Study First Received: February 3, 2000 Last Updated: October 19, 2015 Estimated Primary Completion Date: August 2009 Primary Outcome Measures: Number of Participants With Disease-free Survival|Number of Participants With a Response|Number of Participants With Adverse Events|Percentage of Participants Who Had Paclitaxel and 5-fluorouracil (5-FU) Analysis Performed|Quality of Life Questionnaire Score|Signal Transduction Pathways in Tumor Tissue Versus Normal Tissue Sponsors and Collaborators: National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Result Received: August 30, 2011 Website Link:...

Continue reading
25 April
0 Comments
Sticky

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

Posted by Goldberg, Persky & White P.C.

Condition Mesothelioma|Pancreatic Cancer|Ovarian Cancer|Non-small Cell Lung Cancer Estimated Enrollment: 6 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science Study ID Numbers: MORAb-009-006 Study First Received: January 7, 2011 Last Updated: September 28, 2016 Estimated Primary Completion Date: March 2013 Primary Outcome Measures: Primary Objective: determine biodistribution of radiolabeled amatuximab in tumor and nontumor tissue|Secondary objectives: determine the safety of a single IV of Indium-CHX-A amatuximab|Pharmacokinetic and serum levels|uptake of Indium-CHX-A amatuximab|occurrence of HACA|correlate shed serum mesothelin to imaging Sponsors and Collaborators: Morphotek Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01521325...

Continue reading
25 April
0 Comments
Sticky

Alanosine in Treating Patients With Cancer

Posted by Goldberg, Persky & White P.C.

Condition Lung Cancer|Malignant Mesothelioma|Pancreatic Cancer|Sarcoma Estimated Enrollment: null Age Group: 13 Years and older   (Child, Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: SALMEDIX-SDX-102-01|MSKCC-03029|CDR0000304677 Study First Received: June 5, 2003 Last Updated: June 25, 2013 Estimated Primary Completion Date: December 2005 Primary Outcome Measures: Sponsors and Collaborators: Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00062283...

Continue reading
25 April
0 Comments
Sticky

Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.

Posted by Goldberg, Persky & White P.C.

Condition Lung Cancer|Mesothelioma|Pancreas Cancer|Gastric Cancer Estimated Enrollment: 40 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care Study ID Numbers: CE148/2012 Study First Received: March 1, 2014 Last Updated: July 30, 2015 Estimated Primary Completion Date: April 2014 Primary Outcome Measures: percentage of cancer patients that accept and attend the early palliative care programme|percentage of cancer patients that receive the proposal of early palliative by the oncologists-pneumologists Sponsors and Collaborators: Arcispedale Santa Maria Nuova-IRCCS Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02078700...

Continue reading
25 April
0 Comments
Sticky

Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies

Posted by Goldberg, Persky & White P.C.

Condition Advanced Esophageal Cancers|Primary Small Cell Lung Cancers|Non-Small-Cell Lung Carcinoma|Pleural Mesotheliomas|Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura Estimated Enrollment: 34 Age Group: 18 Years to 65 Years   (Adult) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment Study ID Numbers: 020205|02-C-0205 Study First Received: May 21, 2002 Last Updated: April 19, 2017 Estimated Primary Completion Date: October 8, 2008 Primary Outcome Measures: Pharmacokinetics and toxicity profile Sponsors and Collaborators: National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00037817...

Continue reading
25 April
0 Comments
Sticky

Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs

Posted by Goldberg, Persky & White P.C.

Condition Lung Cancer|Malignant Mesothelioma|Metastatic Cancer Estimated Enrollment: null Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Primary Purpose: Treatment Study ID Numbers: 000088|00-C-0088|CDR0000067718 Study First Received: July 11, 2001 Last Updated: March 14, 2012 Estimated Primary Completion Date: null Primary Outcome Measures: Sponsors and Collaborators: National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00020124...

Continue reading
25 April
0 Comments
Sticky

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

Posted by Goldberg, Persky & White P.C.

Condition Advanced Malignant Mesothelioma|Epithelial Mesothelioma|Localized Malignant Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma Estimated Enrollment: 106 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment Study ID Numbers: NCI-2012-02430|CDR0000069058|NCI-2710|UCCRC-11046A|11046A|2710|N01CM17102|P30CA014599 Study First Received: December 7, 2001 Last Updated: February 10, 2014 Estimated Primary Completion Date: May 2006 Primary Outcome Measures: Time to disease progression|Complete response rate|Objective response rate (complete and partial response)|Rate of disease stabilization|Overall survival|Incidence of adverse events graded according to NCI CTCAE version 3.0 Sponsors and Collaborators: National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00027703...

Continue reading
25 April
0 Comments
Sticky

A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

Posted by Goldberg, Persky & White P.C.

Condition Pancreatic Cancer|Mesothelioma|Ovarian Cancer|Non-Small Cell Lung Cancer Estimated Enrollment: 24 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: MORAb-009-001 Study First Received: May 11, 2006 Last Updated: July 16, 2014 Estimated Primary Completion Date: September 2008 Primary Outcome Measures: Safety and Tolerability as a measure of Adverse Events/Serious Adverse Events|Safety and Tolerability as a measure of clinical laboratory parameters|Safety and Tolerability as a measure of physical examinations, vital signs, and ECGs|Pharmacokinetics of MORAb-009|Percentage of Participants With Antibodies Against Infliximab (Human Anti-chimeric Antibody [HACA])|Objective Tumor Response Rate Assessed by Investigator Sponsors and...

Continue reading